Hims & Hers Health
HIMS
$27.99
+0.36%
Hims & Hers Health, Inc. is a direct-to-consumer telehealth platform founded in 2017 that connects patients with licensed healthcare providers for treatment of conditions including erectile dysfunction, hair loss, dermatology, mental health, and weight loss, offering generic, branded, and compounded prescription medications alongside over-the-counter products and supplements. The company has built a differentiated position as a vertically integrated digital health platform serving more than 2 million subscribers across all 50 states and select European markets, operating without insurance and monetizing entirely through direct consumer payments. The current investor narrative is dominated by the tension between rapid top-line growth — Q2 2026 revenue rose 38.2% year-over-year with management raising full-year 2026 revenue guidance — and a sharp deterioration in profitability, with the most recent quarter swinging to a $92.1 million net loss as the company pivots aggressively into the weight-loss category. This strategic pivot, funded in part by a $350 million convertible debt offering that triggered a double-digit single-day stock decline in May 2026, has made HIMS a high-conviction battleground stock: bulls point to the massive addressable market in GLP-1 and compounded semaglutide access, while bears cite margin compression, dilution risk, and the threat of low-cost generic competition from India reshaping weight-loss drug economics.…
HIMS
Hims & Hers Health
$27.99
Related headlines
Investment Opinion: Should I buy HIMS Today?
The synthesized recommendation is a Hold, reflecting the balanced risk-reward profile. The analyst consensus rating is Hold (mean 2.75) with an average target price of $31.29, implying 11.8% upside from the current price of $27.99. While the revenue growth story is compelling, the sharp deterioration in profitability and the risks associated with the debt-funded expansion warrant caution. The core thesis is that Hims & Hers is a high-growth company navigating a difficult transition, and investors are not adequately compensated for the risks at the current valuation.
Supporting evidence for the Hold rating includes the strong revenue growth of 38.2% year-over-year in Q2 2026, which led to raised full-year guidance. However, the net loss of $92.1 million in Q1 2026 and the negative net margin of -15.1% highlight the profitability challenge. The gross margin remains healthy at 73.8% on a trailing basis, but the quarterly gross margin has fallen to 49.4%, indicating significant pressure from the weight-loss pivot. The forward P/E of 34.3 is elevated relative to the company's earnings growth prospects, and the PEG ratio is negative, suggesting that the market is pricing in high expectations that may not be met. Free cash flow of $75.8 million TTM provides some cushion, but the debt-to-equity ratio of 2.07 is a concern.
The biggest risks that could invalidate the Hold rating include a continued decline in profitability, increased competition from generic weight-loss drugs, and potential dilution from the convertible debt. The rating would upgrade to Buy if the company demonstrates a clear path to profitability, such as achieving positive net income for two consecutive quarters or if the stock price falls below $20, improving the risk-reward. Conversely, a downgrade to Sell would be warranted if revenue growth decelerates below 20% or if the net loss widens further, eroding cash reserves. Relative to its history and peers, the stock appears overvalued given the current earnings trajectory, but the growth potential in telehealth and weight loss could justify a premium if execution improves.
Sign up to view all
HIMS 12-Month Price Forecast
The forward-looking view is neutral, balancing the company's strong revenue growth and large addressable market against its deteriorating profitability and elevated valuation. The base case (50% probability) assumes moderate growth and a return to profitability, supporting a target range of $28-$35. However, the bear case (25%) is significant, with risks from competition and dilution that could drive the stock to $13.74-$23. The bull case (25%) hinges on successful execution and margin recovery, targeting $42-$50. I would upgrade to bullish if the company demonstrates two consecutive quarters of positive net income and stable gross margins above 60%. Conversely, a downgrade to bearish would occur if revenue growth falls below 20% or if the net loss widens further, signaling a failed pivot.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hims & Hers Health's 12-month outlook, with a consensus price target around $31.29 and implied upside of +11.8% versus the current price.
Average Target
$31.29
0 analysts
Implied Upside
+11.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$23 - $42
Analyst target range
Bulls vs Bears: HIMS Investment Factors
The bear case currently has stronger evidence due to the sharp deterioration in profitability, with a $92.1 million net loss in Q1 2026 and negative net margin, alongside a highly leveraged balance sheet and significant dilution risk. However, the bull case is supported by robust revenue growth of 38.2% year-over-year, a raised guidance, and a large addressable market in weight-loss and telehealth. The most critical tension is whether the company can successfully integrate its debt-funded expansion and return to profitability, or if margin compression and competitive pressures will continue to erode shareholder value. The stock's high beta and recent underperformance suggest that sentiment is fragile, and any further earnings misses could trigger additional downside. Ultimately, the investment thesis hinges on the company's ability to achieve sustainable profitability while maintaining its growth trajectory.
Bullish
- Revenue growth remains robust: Q2 2026 revenue rose 38.2% year-over-year, and management raised full-year 2026 revenue guidance. This top-line momentum demonstrates strong demand for Hims & Hers' telehealth offerings, particularly in the high-growth weight-loss category.
- Analyst target implies upside: The average analyst target price is $31.29, representing approximately 11.8% upside from the current price of $27.99. The high target of $42.00 suggests a potential 50.1% gain if the bull case materializes.
- Strong gross margins: Despite recent margin compression, the gross margin remains at 73.8% on a trailing basis, indicating a highly scalable business model with significant pricing power and low marginal costs for digital services.
- Positive free cash flow: Free cash flow on a trailing twelve-month basis is $75.8 million, showing that the core business still generates cash despite the recent net loss. This provides some financial flexibility for growth investments.
Bearish
- Profitability has deteriorated sharply: The most recent quarter (Q1 2026) swung to a net loss of $92.1 million, with a net margin of -15.1%, compared to net income of $49.5 million in Q1 2025. This dramatic reversal raises concerns about the sustainability of the business model amid heavy spending.
- Debt-funded expansion risks dilution: The $350 million convertible debt offering in May 2026 triggered a double-digit stock decline and increases debt-to-equity to 2.07. This raises the risk of shareholder dilution and adds interest burden, pressuring future earnings.
- Extreme volatility and poor relative performance: The stock has a beta of 2.41 and has declined 50.2% over the past year, significantly underperforming the S&P 500's 15.0% gain. The max drawdown of -76.9% highlights the severe downside risk.
- Valuation remains stretched: The trailing P/E is 57.0 and forward P/E is 34.3, which is high for a company with negative earnings growth and a PEG ratio of -33.0. The price-to-book ratio of 13.5 is also elevated, leaving little room for error.
HIMS Technical Analysis
Beta
2.41
2.41x market volatility
Max Drawdown
-76.9%
Largest decline past year
52-Week Range
$14-$65
Price range past year
Annual Return
-50.2%
Cumulative gain past year
| Period | HIMS Return | S&P 500 |
|---|---|---|
| 1m | -10.0% | -0.5% |
| 3m | -21.1% | +2.3% |
| 6m | +27.1% | +16.6% |
| 1y | -50.2% | +14.8% |
| ytd | -16.2% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HIMS Fundamental Analysis
Quarterly Revenue
$608104000.0B
2026-03
Revenue YoY Growth
+3.8%
YoY Comparison
Gross Margin
49.4%
Latest Quarter
Free Cash Flow
$75838000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HIMS Overvalued?
PE
57.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 13x~90x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
45.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant, primarily stemming from the company's deteriorating profitability and increased leverage. The most recent quarter reported a net loss of $92.1 million, a stark reversal from the $49.5 million profit in the prior-year period, with a net margin of -15.1%. The debt-to-equity ratio has climbed to 2.07 following the $350 million convertible debt offering, which could lead to shareholder dilution and higher interest expenses. Additionally, the company's aggressive pivot into weight-loss drugs has compressed gross margins from 73.8% to 49.4% in Q1 2026, indicating pricing pressure and higher costs associated with compounded medications. These factors collectively heighten the risk of continued earnings volatility and potential cash burn if the expansion does not yield expected returns.
Market and competitive risks are amplified by the stock's high beta of 2.41, making it highly sensitive to market swings and sector rotation. The telehealth and weight-loss markets are becoming increasingly crowded, with Novo Nordisk securing FDA approval for a higher-dose Wegovy and low-cost generic semaglutide from India threatening to reshape the economics of weight-loss drugs. Hims & Hers faces the challenge of differentiating its offerings while maintaining margins, and any loss of market share could lead to further revenue deceleration. Furthermore, the broader market environment, with persistent inflation and repriced rate-cut expectations, pressures high-multiple growth stocks, and HIMS's premium valuation (forward P/E of 34.3) leaves it vulnerable to multiple compression.
In a worst-case scenario, a combination of intensifying competition, failed expansion, and continued losses could drive the stock down to its 52-week low of $13.74, representing a 50.9% decline from the current price of $27.99. This scenario could unfold if the company fails to achieve profitability, faces regulatory setbacks, or experiences a significant loss of subscribers. The analyst low target of $23.00 also implies a 17.8% downside, but the 52-week low reflects a more severe outcome. Given the max drawdown of -76.9%, investors could lose more than half of their investment if bearish conditions materialize. Such a decline would be exacerbated by the stock's high volatility and potential forced selling by leveraged holders.
FAQ
The key risks for HIMS include financial, competitive, and regulatory challenges. Financially, the company reported a net loss of $92.1 million in Q1 2026 and has a debt-to-equity ratio of 2.07, which could lead to dilution or financial distress if losses continue. Competitively, the entry of low-cost generic semaglutide from India and Novo Nordisk's higher-dose Wegovy approval threaten to erode HIMS's market share and pricing power in the weight-loss segment. Regulatory risks include potential crackdowns on compounded GLP-1 medications, which are a significant part of HIMS's offering. Additionally, the stock's high beta of 2.41 makes it vulnerable to market volatility, and its 50.2% decline over the past year reflects poor relative performance. These risks are ranked from highest to lowest severity: financial sustainability, competitive pressure, regulatory changes, and market volatility.
The 12-month forecast for HIMS includes three scenarios: a bull case with 25% probability targeting $42-$50, a base case with 50% probability targeting $28-$35, and a bear case with 25% probability targeting $13.74-$23. The base case is most likely, assuming revenue growth moderates to 25-30% and the company achieves breakeven profitability by late 2026. The bull case depends on successful weight-loss product adoption and margin recovery, while the bear case hinges on intensifying competition and continued losses. The analyst average target of $31.29 aligns with the base case, implying 11.8% upside. Key assumptions include stable gross margins above 60% and no further equity dilution. Investors should watch for quarterly earnings to gauge progress toward these scenarios.
HIMS appears overvalued based on traditional metrics, with a trailing P/E of 57.0 and a forward P/E of 34.3, which are high relative to the company's current earnings growth. The price-to-book ratio of 13.5 and price-to-sales ratio of 3.11 also suggest a premium valuation. The PEG ratio is negative (-33.0), indicating that earnings are expected to decline in the near term, which does not justify the high multiple. However, the market may be pricing in future growth from the weight-loss segment, which could be substantial if executed well. Compared to peers in the telehealth space, HIMS trades at a premium, but its direct-to-consumer model and brand recognition could warrant a higher multiple if margins recover. Currently, the valuation implies that the market expects rapid revenue growth and a return to profitability, leaving little room for error.
HIMS presents a high-risk, high-reward opportunity that is not suitable for all investors. The stock trades at $27.99, with an average analyst target of $31.29 (11.8% upside) and a high target of $42 (50.1% upside), but the downside risk is substantial, with a 52-week low of $13.74 (-50.9%). The company's revenue growth of 38.2% year-over-year is impressive, but the recent net loss of $92.1 million and negative net margin of -15.1% raise concerns about profitability. The debt-to-equity ratio of 2.07 and the $350 million convertible debt offering add dilution risk. For investors with a high risk tolerance and a long-term view, a small position could be justified if they believe in the telehealth and weight-loss growth story. However, those seeking stable returns or income should avoid HIMS until it demonstrates consistent profitability.
HIMS is more suitable for long-term investment for investors with a high risk tolerance, given its growth stage and volatile earnings. The company is in a transitional phase, investing heavily in weight-loss expansion, which may take several quarters to pay off. Its beta of 2.41 indicates high volatility, making it less ideal for short-term trading unless one can actively manage risk. The lack of a dividend (payout ratio 0) means returns depend entirely on capital appreciation. Earnings visibility is low due to competitive and regulatory uncertainties, so a long-term horizon of at least 3-5 years is recommended to ride out potential drawdowns. Short-term traders might capitalize on volatility, but the risk of sharp declines (e.g., -76.9% max drawdown) is significant. A minimum holding period of 2-3 years would allow the company to stabilize profitability and demonstrate sustainable growth.